CATALOGO DEI PRODOTTI DELLA RICERCA

TORTORA, GIAMPAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 16.988
NA - Nord America 15.259
AS - Asia 11.103
SA - Sud America 1.570
AF - Africa 169
OC - Oceania 40
Continente sconosciuto - Info sul continente non disponibili 30
Totale 45.159
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.017
RU - Federazione Russa 6.468
GB - Regno Unito 4.515
SG - Singapore 4.428
CN - Cina 4.089
BR - Brasile 1.258
HK - Hong Kong 998
DE - Germania 987
IE - Irlanda 967
SE - Svezia 962
FR - Francia 943
IT - Italia 908
VN - Vietnam 692
FI - Finlandia 682
KR - Corea 219
UA - Ucraina 158
AR - Argentina 122
CA - Canada 117
JP - Giappone 104
NL - Olanda 99
IN - India 98
ID - Indonesia 87
MX - Messico 77
TR - Turchia 69
ZA - Sudafrica 67
BD - Bangladesh 62
BE - Belgio 53
PL - Polonia 53
EC - Ecuador 48
IQ - Iraq 44
ES - Italia 40
AU - Australia 31
MA - Marocco 31
AT - Austria 28
CO - Colombia 28
VE - Venezuela 28
EU - Europa 27
UZ - Uzbekistan 26
CL - Cile 23
PY - Paraguay 23
IR - Iran 22
PE - Perù 20
SA - Arabia Saudita 20
AE - Emirati Arabi Uniti 18
CH - Svizzera 17
KE - Kenya 14
LT - Lituania 14
UY - Uruguay 14
EG - Egitto 12
JO - Giordania 12
AZ - Azerbaigian 11
CR - Costa Rica 11
CZ - Repubblica Ceca 10
NP - Nepal 10
PK - Pakistan 10
KG - Kirghizistan 9
LK - Sri Lanka 9
IL - Israele 8
LV - Lettonia 8
MY - Malesia 8
PH - Filippine 8
RO - Romania 8
TN - Tunisia 8
AL - Albania 7
NZ - Nuova Zelanda 7
BG - Bulgaria 6
BJ - Benin 6
DZ - Algeria 6
EE - Estonia 6
GR - Grecia 6
GT - Guatemala 6
JM - Giamaica 6
KZ - Kazakistan 6
DK - Danimarca 5
HN - Honduras 5
HU - Ungheria 5
NO - Norvegia 5
SK - Slovacchia (Repubblica Slovacca) 5
SN - Senegal 5
BO - Bolivia 4
MK - Macedonia 4
PT - Portogallo 4
TG - Togo 4
TT - Trinidad e Tobago 4
AM - Armenia 3
AO - Angola 3
BA - Bosnia-Erzegovina 3
BB - Barbados 3
BH - Bahrain 3
BY - Bielorussia 3
DO - Repubblica Dominicana 3
KH - Cambogia 3
KW - Kuwait 3
LB - Libano 3
LU - Lussemburgo 3
PS - Palestinian Territory 3
TH - Thailandia 3
TW - Taiwan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
CI - Costa d'Avorio 2
Totale 45.115
Salva come PNG Salva come JPEG
Città #
Southend 4.163
Singapore 2.009
Moscow 1.985
Chandler 1.850
Dallas 1.562
Jacksonville 1.437
Woodbridge 1.406
Ashburn 1.017
Ann Arbor 1.008
Hong Kong 987
Dublin 962
Beijing 731
Houston 610
Lawrence 396
Princeton 396
The Dalles 385
Wilmington 379
Jinan 322
Los Angeles 311
Nanjing 279
New York 278
Shenyang 260
Verona 220
Ho Chi Minh City 208
Tianjin 188
Munich 187
Hebei 166
Buffalo 155
São Paulo 142
Changsha 135
Redondo Beach 131
Hanoi 118
Nanchang 107
Columbus 100
Helsinki 100
Santa Clara 97
Zhengzhou 97
Haikou 93
Tokyo 89
Ningbo 88
Milan 86
Guangzhou 85
Sindelfingen 83
Hangzhou 82
Dong Ket 78
Jiaxing 75
Turku 67
Taizhou 60
Redwood City 58
Seoul 58
Jakarta 57
San Francisco 57
Taiyuan 57
Brooklyn 55
Norwalk 55
Brussels 53
London 51
Montreal 51
Chicago 49
Boardman 47
Denver 47
Seattle 46
Stockholm 44
Lanzhou 43
Warsaw 42
Bologna 41
Johannesburg 41
Fuzhou 39
Frankfurt am Main 38
Lancaster 38
Falls Church 34
Mexico City 34
Rio de Janeiro 34
Chennai 33
Dearborn 33
Atlanta 32
Phoenix 31
Council Bluffs 30
Redmond 29
Kent 28
Orem 28
Amsterdam 27
Boston 27
Campinas 27
Belo Horizonte 26
Dongguan 26
Haiphong 25
Washington 25
Nuremberg 24
Poplar 23
Toronto 23
Rome 22
Tashkent 22
Biên Hòa 21
Baghdad 20
Curitiba 19
Düsseldorf 19
Augusta 18
Brasília 18
Charlotte 18
Totale 27.613
Salva come PNG Salva come JPEG
Nome #
An FGFR3 autocrine loop sustains acquired resistance to trastuzumab in gastric cancer patients 287
A clinical-biological risk stratification model for resected gastric cancer: prognostic impact of Her2, Fhit, and APC expression status 259
A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma 258
Whole-genome landscape of pancreatic neuroendocrine tumours 252
Combined inhibition of IL1, CXCR1/2, and TGFβ signaling pathways modulates in-vivo resistance to anti-VEGF treatment 237
Acquired hemophagocytic syndrome in a patient with synovial sarcoma: a case report 221
True 3q Chromosomal Amplification in Squamous Cell Lung Carcinoma by FISH and aCGH Molecular Analysis: Impact on Targeted Drugs 218
ALK gene copy number in lung cancer: Unspecific polyploidy versus specific amplification visible as double minutes 216
Genomic analyses identify molecular subtypes of pancreatic cancer 216
BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing 214
ALK/EML4 Fusion Gene May Be Found in Pure Squamous Carcinoma of the Lung 212
Molecular typing of lung adenocarcinoma on cytological samples using a multigene next generation sequencing panel 211
Ampulla of Vater Carcinoma: Sequencing Analysis Identifies TP53 Status as a Novel Independent Prognostic Factor and Potentially Actionable ERBB, PI3K, and WNT Pathways Gene Mutations 211
Can histogram analysis of MR images predict aggressiveness in pancreatic neuroendocrine tumors? 211
High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers 209
Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling 202
Cathepsin K expression in castration-resistant prostate carcinoma: a therapeutical target for patients at risk for bone metastases 199
Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplification 193
Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups 193
Perfusion Changes in Liver Metastases (LM) from Pancreatic Neuroendocrine Tumors (PanNETs) during Everolimus (E) Treatment: Update of Perfusion CT (P-CT) Study 191
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer 188
Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis 187
The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies 187
Tumor thrombosis: a peculiar finding associated with pancreatic neuroendocrine neoplasms. A pictorial essay 187
Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation 183
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers 182
Next-generation repeat-free FISH probes for DNA amplification in glioblastoma in vivo: Improving patient selection to MDM2-targeted inhibitors 181
Adenocarcinoma of the paraurethral glands: a case report 180
Corrigendum: Whole-genome landscape of pancreatic neuroendocrine tumours 178
Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies 176
Angiopoietin-Like Proteins in Angiogenesis, Inflammation and Cancer 176
Reporting tumor molecular heterogeneity in histopathological diagnosis 176
FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma. 174
Reprofiling Metastatic Samples for Chromosome 9p and 14q Aberrations as a Strategy to Overcome Tumor Heterogeneity in Clear-cell Renal Cell Carcinoma 174
A selective cyclooxygenase-2 inhibitor combined with the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 ('Iressa') and protein kinase A antisense causes cooperative tumor growth inhibition after oral administration 173
Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 assay according to histology: prognostic relevance for resected early stage 'pure' and 'mixed' lobular breast cancer 173
Tumor Perfusion Changes During Everolimus (E) Treatment: Preliminary Results from Perfusion-CT (P-CT) Study 172
The Tumor Entity Denominated "clear cell-papillary renal cell carcinoma" According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome 172
Adjuvant Chemotherapy For Resected Non-Small-Cell Lung Cancer: Future Perspectives For Clinical Research 171
Methods to identify molecular expression of mTOR pathway: a rationale approach to stratify patients affected by clear cell renal cell carcinoma for more likely response to mTOR inhibitors. 170
Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials 169
Evaluation of cell-free DNA as a biomarker for pancreatic malignancies 168
The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer 168
The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinoma 167
An angiopoietin-like protein 2 autocrine signaling promotes EMT during pancreatic ductal carcinogenesis 167
Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: 'Game Over'? 167
A novel modified CpG agonist of TLR-9 inhibits EGF receptor signalling and synergistically enhances antitumor activity of cetuximab and irinotecan eradicating colon cancer xenografts 166
Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients 166
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 165
Investigating BRCA Mutations: A Breakthrough in Precision Medicine of Castration-Resistant Prostate Cancer 165
Perfusion CT Changes in Liver Metastases from Pancreatic Neuroendocrine Tumors During Everolimus Treatment 165
Neoadjuvant strategies for triple negative breast cancer: 'state-of-the-art' and future perspectives 165
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas 164
Prognostic impact of early nutritional support in patients affected by locally advanced and metastatic pancreatic ductal adenocarcinoma undergoing chemotherapy 164
Addressing the expected survival benefit for clinical trial design in metastatic castration-resistant prostate cancer: Sensitivity analysis of randomized trials 164
Pancreatic neuroendocrine neoplasms: Magnetic resonance imaging features according to grade and stage 164
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma 163
Role of Combined Ga-68-DOTATOC and F-18-FDG Positron Emission Tomography/Computed Tomography in the Diagnostic Workup of Pancreas Neuroendocrine Tumors Implications for Managing Surgical Decisions 163
Pancreatic Cancer and Obesity: Molecular Mechanisms of Cell Transformation and Chemoresistance 163
The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives 162
Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. 162
Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. 161
Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice 160
ESGAR 2016 Book of Abstracts 160
Organoid-Transplant Model Systems to Study the Effects of Obesity on the Pancreatic Carcinogenesis in vivo 160
Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Heat Shock Protein 90 Overexpression, Ki67 Proliferative Index, and Topoisomerase II-α Co-amplification as Predictors of Pathologic Complete Response to Neoadjuvant Chemotherapy With Trastuzumab and Docetaxel 160
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. 158
HER2/neu Gene Determination in Women Screened for Breast Carcinoma: How Screening Programs Reduce the Skyrocketing Cost of Targeted Therapy 157
Hypermutation In Pancreatic Cancer 157
Comparison Between Prognostic Classifications in De Novo Metastatic Hormone Sensitive Prostate Cancer 157
Prognostic Value of Beta-Tubulin-3 and c-Myc in Muscle Invasive Urothelial Carcinoma of the Bladder 157
Gene expression profiling of lung atypical carcinoids and large cell neuroendocrine carcinomas identifies three transcriptomic subtypes with specific genomic alterations 157
Current Strategies to Overcome Resistance to ALK-Inhibitor Agents 156
Prognostication and response assessment in liver and pancreatic tumors: The new imaging 155
Lung neuroendocrine tumours: deep sequencing of the four WHO histotypes reveals chromatin remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D 154
De novo metastatic castration sensitive prostate cancer: State of art and future perspectives 154
The development of PARP as a successful target for cancer therapy 153
Wide spetcrum mutational analysis of metastatic renal cell cancer: a retrospective next generation sequencing approach 153
Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. 152
Preliminary results of PRINCiPe (predictors of resistance to immunotherapy with nivolumab [NIV]) study in advanced pretreated non-small cell lung cancer (APNSCLC), investigating the role of an immune genomic signature (IGS) including JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2 alterations 152
Balancing activity and tolerability of neoadjuvant paclitaxel- and docetaxel-based chemotherapy for HER2-positive early stage breast cancer: Sensitivity analysis of randomized trials 152
Tumor seeding after percutaneous US-guided FNA of solid pancreatic neoplasms 151
Renal cell carcinoma in one year: Going inside the news of 2017 - A report of the main advances in RCC cancer research 151
AGENTI BIOLOGICI e CHEMIOTERAPICI: INTEGRAZIONE 150
Immunotherapy versus standard of care in metastatic renal cell carcinoma. A systematic review and meta-analysis 150
AR-V7 and prostate cancer: The watershed for treatment selection? 149
Adjuvant therapy for resected early-stage small-cell lung cancer: is now time to rethink about that? 149
TAK1-regulated expression of BIRC3 predicts resistance to preoperative chemoradiotherapy in oesophageal adenocarcinoma patients 148
Molecular Pathology of Pancreatic Cancer: from bench-to-bedside translation. 147
8-Chloro-cAMP inhibits transforming growth factor alpha transformation of mammary epithelial cells by restoration of the normal mRNA patterns for cAMP-dependent protein kinase regulatory subunit isoforms which show disruption upon transformation. 146
A propensity score analysis exploring the impact of adjuvant chemotherapy (aCT) in a multi-center series of resected early stage pure invasive lobular breast carcinoma (ILC) 146
The route to personalized medicine in bladder cancer: where do we stand? 145
Tubulin inhibitors in non-small cell lung cancer: looking back and forward 144
2015 and human cancer: back to overall survival 144
A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. 143
Tumor Perfusion Changes During Everolimus (E) Treatment: Preliminary Results from Perfusion-CT (P-CT) Study 143
Angiogenesis: A target for cancer therapy. 142
Anti-Angiogenic Drugs and Biomarkers in Non-Small-Cell Lung Cancer: A 'Hard Days Night' 142
Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors 139
Pancreatic neuroendocrine neoplasms: MRI features and correlation with their histological grade 139
Totale 17.330
Salva come PNG Salva come JPEG
Categoria #
all - tutte 155.270
article - articoli 141.089
book - libri 420
conference - conferenze 10.485
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 3.276
Totale 310.540
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.133 0 0 0 0 0 235 33 152 143 76 306 188
2021/20222.725 202 780 17 208 94 46 41 175 109 61 198 794
2022/20235.491 472 505 554 860 534 1.409 54 323 582 36 118 44
2023/20242.404 103 200 180 202 381 380 51 232 45 125 353 152
2024/20257.291 400 446 238 1.317 252 196 248 310 1.242 490 585 1.567
2025/202614.075 1.660 1.073 1.729 3.557 5.247 809 0 0 0 0 0 0
Totale 45.568